GlassScriptPhysician profile
Muhammad S Alam
NPI 1194731224
$5,607.14
in general payments reported to CMS, 2019-2025
32 companies · $965 in 2025
The $965 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $444 · 2021: $824 · 2022: $1,357 · 2023: $804 · 2024: $522 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.42 |
| Education | $167.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $938.58 | 2019-2023 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $922.65 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $439.58 | 2020-2023 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $416.38 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $325.09 | 2019-2023 | Rayaldee |
| Akebia Therapeutics INC | $324.12 | 2022-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $312.40 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $301.46 | 2022-2025 | Tarpeyo |
| Amgen INC. | $229.27 | 2019-2025 | Tavneos, Epogen, Parsabiv |
| Mallinckrodt Enterprises LLC | $152.21 | 2019 | |
| Glaxosmithkline, LLC. | $146.58 | 2021-2025 | Benlysta, Jesduvroq, Shingrix |
| Otsuka America Pharmaceutical, INC. | $145.69 | 2021-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.62 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $96.87 | 2023-2025 | Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $94.92 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $82.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.04 | 2021-2022 | |
| Genzyme Corporation | $66.61 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $59.53 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $58.50 | 2022-2023 | Purified Cortrophin Gel |
| Ardelyx, INC. | $54.99 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $48.47 | 2022 | |
| Renalytix Ai, INC. | $36.95 | 2022-2023 | Kidneyintelx Blood Collection Convenience Kit |
| Cycle Pharmaceuticals INC | $27.49 | 2025 | Venxxiva |
| Spectrum Pharmaceuticals INC. | $24.43 | 2019 | |
| Genentech USA, INC. | $24.04 | 2025 | Gazyva |
| Kyowa Kirin, INC. | $22.56 | 2023 | Crysvita |
| Alnylam Pharmaceuticals INC. | $20.93 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.94 | 2024 | Keveyis |
| Abbvie INC. | $13.99 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.71 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.